Journal of Developing Drugs
Open Access
ISSN: 2329-6631
ISSN: 2329-6631
Edith Cristina Laignier Cazedey
Federal University of Bahia, Brazil
Posters-Accepted Abstracts: J Develop Drugs
A lot of new drugs and medicines have an excellent pharmacokinetic/pharmacodynamic, effectiveness and many advantages. However, analytical methods for quantitative determination of them are not always available. It is known that poor quality of API and medicines are directly related to development of side effects and toxics events. Thus, it is important to develop efficient analytical methods for quality control of commercialized products. My research group works with development of analytical methods for qualitative analysis of drugs and medicines using UV/VIS/IR spectrophotometry, high performance liquid chromatography, thermal analysis, thin layer chromatography and other general methods for characterization of API and pharmaceutical forms. Analytical methods such as UV spectrophotometry, stability indicating high performance liquid chromatography and microbiological agar diffusion and turbidimetry are also developed and validated for quantitation of API and pharmaceutical forms. All validation parameters reach the requirements of the major guides and pharmacopoeias. The dissolution tests and dissolution kinetics are also developed. Stability studies of API and pharmaceutical forms are conducted to evaluate the susceptibility of them to acid, basic and neutral hydrolysis, oxidation and photolysis in acid, basic and neutral aqueous solutions, besides the photolysis and thermal degradation testes. Preliminary studies of accelerated stability and long-term stability are also performed. The degradation products are identified using liquid chromatography��?mass spectrometry method.
Email: crislaignier@yahoo.com.br